Mometasone furoate ( DrugBank: Mometasone, Mometasone furoate )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
98	Eosinophilic gastrointestinal disease	3
162	Pemphigoid	1

98. Eosinophilic gastrointestinal disease

---

Clinical trials : 171 /  Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-000082-16-DE (EUCTR)	21/01/2021	29/07/2020	A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagus	A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis	Active eosinophilic esophagitis MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: ESO-101 Product Code: ESO-101 INN or Proposed INN: mometasone Other descriptive name: MOMETASONE FUROATE	EsoCap AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	42	Phase 2	Spain;Netherlands;Germany;Switzerland
2	EUCTR2020-000082-16-NL (EUCTR)	29/10/2020	03/09/2020	A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagus	A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis	Active eosinophilic esophagitis MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: ESO-101 Product Code: ESO-101 INN or Proposed INN: mometasone Other descriptive name: MOMETASONE FUROATE	EsoCap AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	42	Phase 2	Spain;Germany;Netherlands;Switzerland
3	NCT02113267 (ClinicalTrials.gov)	April 2014	10/4/2014	Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.	Treatment of Eosinophilic Esophagitis With Mometason Furoat Aerosol: a Randomised, Placebo-controled Phase II Study for Evaluation of Treatment Effect on Group Level Including Symtom Questionnaires	Eosinophilic Esophagitis	Drug: Mometasone furoate;Drug: Placebo	Mogens Bove	Vastra Gotaland Region	Terminated	18 Years	N/A	All	40	Phase 2	Sweden

162. Pemphigoid

---

Clinical trials : 83 /  Drugs : 128 - (DrugBank : 51) / Drug target genes : 33 - Drug target pathways : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04499235 (ClinicalTrials.gov)	January 30, 2020	31/7/2020	A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid	Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid	Pemphigoid, Bullous	Drug: Mometasone furoate;Drug: AKST4290;Drug: Placebo	Alkahest, Inc.	NULL	Completed	60 Years	95 Years	All	30	Phase 2	Germany